-Hyperbaric oxygen (HBO) is a major therapeutic treatment for ischemic ulcerations that perforate skin and underlying muscle in diabetic patients. These lesions do not heal effectively, in part, because of the hypoxic microvascular O 2 partial pressures (PmvO 2 ) resulting from diabetes-induced cardiovascular dysfunction, which alters the dynamic balance between O 2 delivery (Q O2) and utilization (V O2) rates. We tested the hypothesis that HBO in diabetic muscle would exacerbate the hyperoxic Pmv O 2 dynamics due, in part, to a reduction or slowing of the cardiovascular, sympathetic nervous, and respiratory system responses to acute HBO exposure. Adult male Wistar rats were divided randomly into diabetic (DIA: streptozotocin ip) and healthy (control) groups. A small animal hyperbaric chamber was pressurized with oxygen (100% O 2) to 3.0 atmospheres absolute (ATA) at 0.2 ATA/min. Phosphorescence quenching techniques were used to measure Pmv O 2 in tibialis anterior muscle of anesthetized rats during HBO. Lumbar sympathetic nerve activity (LSNA), heart rate (HR), and respiratory rate (RR) were measured electrophysiologically. During the normobaric hyperoxia and HBO, DIA tibialis anterior Pmv O 2 increased faster (mean response time, CONT 78 Ϯ 8, DIA 55 Ϯ 8 s, P Ͻ 0.05) than CONT. Subsequently, Pmv O 2 remained elevated at similar levels in CONT and DIA muscles until normobaric normoxic recovery where the DIA Pmv O 2 retained its hyperoxic level longer than CONT. Sympathetic nervous system and cardiac and respiratory responses to HBO were slower in DIA vs. CONT. Specifically the mean response times for RR (CONT: 6 Ϯ 1 s, DIA: 29 Ϯ 4 s, P Ͻ 0.05), HR (CONT: 16 Ϯ 1 s, DIA: 45 Ϯ 5 s, P Ͻ 0.05), and LSNA (CONT: 140 Ϯ 16 s, DIA: 247 Ϯ 34 s, P Ͻ 0.05) were greater following HBO onset in DIA than CONT. HBO treatment increases tibialis anterior muscle Pmv O 2 more rapidly and for a longer duration in DIA than CONT, but not to a greater level. Whereas respiratory, cardiovascular, and LSNA responses to HBO are profoundly slowed in DIA, only the cardiovascular arm (via HR) may contribute to the muscle vascular incompetence and these faster Pmv O 2 kinetics. (10)-mediated mechanisms, and it is pertinent that chemoreflex (11) and baroreflex control in experimental diabetes is impaired (9, 39). Thus, HBO-induced respiratory, cardiovascular, and baroreflex dysfunction in diabetes can, in addition to altered muscle vascular control, affect the dynamic balance between O 2 delivery (Q O 2 ) and utilization (V O 2 ) [i.e., Pmv O 2 (31, 32)] in skeletal muscle of diabetic patients. An important perspective here is that Pmv O 2 constitutes the sole driving force for blood-tissue O 2 flux, and therefore the beneficial effects of HBO are contingent on Pmv O 2 rising appropriately with HBO. Thus, in understanding the therapeutic potential of HBO, it is important to resolve the time course(s) of Pmv O 2 and these processes (i.e., their kinetics) and gain some insight into their potential to impact tissue Pmv O 2 responses to HBO.
moglobin (Hb) O 2 saturation to 100% (from ϳ97% or lower) and enhancing dissolved O 2 in the plasma, which acts to alleviate tissue hypoxia and may initiate crucial angiogenic and tissue restorative pathways (21) . With HBO arterial PO 2 should increase roughly in proportion to inspired O 2 pressure. However, HBO is also associated with altered breathing [i.e., transient hypopnea (46) ] and cardiovascular responses such as vasoconstriction (41) , bradycardia, and decreased cardiac output (15, 45) . These effects of HBO are coordinated through chemoreflex (reviewed in Ref. 46 )-and baroreflex (10)-mediated mechanisms, and it is pertinent that chemoreflex (11) and baroreflex control in experimental diabetes is impaired (9, 39) . Thus, HBO-induced respiratory, cardiovascular, and baroreflex dysfunction in diabetes can, in addition to altered muscle vascular control, affect the dynamic balance between O 2 delivery (Q O 2 ) and utilization (V O 2 ) [i.e., Pmv O 2 (31, 32) ] in skeletal muscle of diabetic patients. An important perspective here is that Pmv O 2 constitutes the sole driving force for blood-tissue O 2 flux, and therefore the beneficial effects of HBO are contingent on Pmv O 2 rising appropriately with HBO. Thus, in understanding the therapeutic potential of HBO, it is important to resolve the time course(s) of Pmv O 2 and these processes (i.e., their kinetics) and gain some insight into their potential to impact tissue Pmv O 2 responses to HBO.
Underlying the physical and metabolic dysfunction in diabetes is the induction of profound structural and functional alterations that impact the capability of the oxygen (O 2 ) transport system to deliver sufficient O 2 (Q O 2 ) to meet the metabolic requirements (V O 2 ) especially of skeletal muscle at rest and during exercise. Thus, Type 1 diabetes induces muscle atrophy, capillary rarefaction, and impaired vascular and capillary hemodynamics as well as reduced muscle oxidative capacity (3, 16, 38) . Type 2 diabetes also presents a severe impairment of arterial (19, 34) and microcirculatory (27, 28) hemodynamics in skeletal muscle at rest and during exercise. Key contributors to this condition are thought to include upregulation of endothelin-1 (37), prostaglandin (1) , and myogenic (43) vasoconstrictor pathways combined with downregulation of vasodilatory endothelial function and nitric oxide bioavailability (17, 24, 48) . Given the above, it is not surprising that the dynamics of Q O 2 , following exercise onset, for example, may be deficient as evidenced by the aberrant Pmv O 2 profile to muscle contractions, which reflects an imbalance between Q O 2 and V O 2 responses [type I (3); type 2 (28) ]. However, these altered dynamics do not ipso facto mean that diabetic muscle cannot modulate its steady-state blood flow (and thus Q O 2 and Pmv O 2 ) appropriately either at rest or in response to altered metabolic demands (8) .
To date, the response of diabetic muscle Pmv O 2 to HBO therapy has never been determined. Therefore, we sought to characterize the temporal profile of muscle Pmv O 2 together with respiratory and cardiovascular responses to HBO [1.0 -3.0 atmospheres absolute (ATA)] in healthy and diabetic rats. Specifically, we tested the hypothesis that HBO in diabetic muscle would: 1) speed and accentuate the hyperoxic Pmv O 2 dynamics and that 2) these responses would relate temporally to a reduction or slowing of the cardiovascular, sympathetic nervous [assessed via lumbar sympathetic nerve activity (LSNA)], and respiratory system responses to acute HBO exposure.
MATERIALS AND METHODS

Animals
Male Wistar rats (total n ϭ 36, 10 wk of age; Japan SLC, Shizuoka, Japan) were used in this study. Rats were maintained on a 12:12-h light-dark cycle and received food and water ad libitum. Rats were divided into the following two groups: healthy control (CONT) and diabetic (DIA) rats. Rats were anesthetized using isoflurane and given intraperitoneal injection of 45 mg/kg body wt of streptozotocin (STZ; S0130; Sigma-Aldrich, St. Louis, MO) prepared fresh in saline solution. CONT animals were injected with saline vehicle. Urine glucose levels of rats were measured (New Uriesu Ga, Terumo, Japan) 2 days after STZ injection with the onset of diabetes raising glucose concentrations above 500 mg/dl. These measurements of urine glucose were continued each week for 4 wk. After 4 wk post-STZ, blood was collected from a tail vein puncture to confirm that the blood glucose level exceeded 300 mg/dl. All experiments were conducted under the guidelines established by the Physiological Society of Japan and were approved by the University of Electro-Communications Institutional Animal Care and Use Committee. The rats were anesthetized using pentobarbital sodium (60 mg/kg ip), and supplemental doses of anesthesia were administered as needed. At the end of experimental protocols, animals were killed by pentobarbital sodium overdose.
HBO Exposures
Rats were placed in the small animal hyperbaric chamber in the prone position. During measurement of oxygen pressures in the tibialis anterior muscle the ankle joint was fixed at 90°. To maintain body temperature a 37°C thermal pad (Deltaphase isothermal pad; Braintree Scientific, Braintree, MA) was placed over the abdominal region. Each rat was instrumented and stabilized before collection of the normoxic normobaric baseline measurements. Subsequently, the HBO protocol shown in Fig. 1 was initiated. Following return to normobaric normoxia a further 5 min of monitoring were performed (i.e., Post 1-4). O 2 (100%) was instilled in the small animal hyperbaric chamber from an oxygen tank by regulating the flow control valve, and the chamber was pressurized to 3.0 ATA at 0.2 ATA/min. Subsequently, the chamber was depressurized at 0.2 ATA/min. This protocol is more gradual than rat models of decompression sickness (30, 44) where peak pressure is set at 10.0 ATA and compression and decompression rate at 1.0 ATA/min and does not lead to gas bubbles.
Measurement Protocol 1: Pmv O 2 Measurement (n ϭ 13)
Surgical preparation for phosphorescence quenching. Before the surgical procedures, the animals were anesthetized with pentobarbital sodium. The rat was placed on a heating pad (37°C) to maintain body temperature. The left carotid artery was cannulated (PE-50) for infusion of the phosphorescent probe [palladium meso-tetra(4-carboxyphenyl)porphyrin dendrimer (R2)] at 15 mg/kg body wt. The tibialis anterior muscle was exposed to provide measurement of Pmv O 2 . After the overlying skin was reflected and the fascia was removed, the muscle surface was superfused with Krebs-Henseleit solution equilibrated with 5% CO 2-95% N2 at 38°C and adjusted to pH 7.4. The phosphor R2 was infused via the arterial cannula ϳ15 min before initiation of the experiments, which were conducted in a darkened room to prevent contamination from ambient light.
Pmv O 2 measurements. PmvO 2 was determined at 1-s intervals at rest and during HBO. The theoretical basis for phosphorescence quenching has been detailed previously (4, 5, 36) . Briefly, the Stern-Volmer relationship (36) describes quantitatively the O 2 dependence of the phosphorescent probe. R2 is a nontoxic dendrimer (18) that binds completely to albumin at 38°C and pH 7.4, with a quenching constant of 409 Torr Ϫ1 /s and lifetime of decay in the absence of O2 of 601 s under the physiological conditions extant herein (20, 29) . In addition to binding with albumin, the net negative charge of R2 helps facilitate restriction of R2 to the intravascular space (31) . To determine Pmv O 2 , a PMOD 2000 frequency domain phosphorometer (Oxygen Enterprises, Philadelphia, PA) was used; the common end of the bifurcated light guide was placed ϳ2-3 mm above the medial region of the tibialis anterior muscle, and blood was sampled within the microvasculature up to over 0.5 mm deep within a circular region ϳ2 mm in diameter.
The phosphorometer employs a sinusoidal modulation of the excitation light (524 nm) at frequencies between 100 Hz and 20 kHz, which allows for phosphorescence lifetime measurements from 10 s to ϳ2.5 ms. In the single-frequency mode, 10 scans (100 ms) were used to acquire the resultant lifetime of the phosphorescence (700 nm) and were repeated every 1 s. To obtain the phosphorescence lifetime, the logarithm of the intensity values was taken at each time point, and the linearized decay was fit to a straight line by least-squares regression analysis.
Modeling of Pmv O 2 profiles. Curve fitting (HBO pressurization phase) was accomplished using KaleidaGraph software (Synergy Software, Reading, PA) and was performed on the PmvO 2 data using a one-component model:
where PmvO 2 (t) is a given time point, PmvO 2 (baseline) is baseline (i.e., pre-HBO), and ⌬PmvO 2 is the increase in PmvO 2 from baseline to the peak O2 inhalation condition (i.e., 3.0 ATA, 100% O2) values. TD is the time delay, and is the time constant. To determine whether the one component would adequately describe the PmvO 2 response the goodnessof-fit for the model was determined via the following three criteria: 1) the coefficient of determination (i.e., r 2 ), 2) the sum of the squared residuals term (i.e., 2 ), and 3) visual inspection of the model fit to the data.
Measurement Protocol 2: Electrophysiological Measurement (n ϭ 9)
Heart rate and respiration rate. Electrical signals were recorded using Teflon-coated stainless steel needle electrodes (A-M Systems, Carlsborg, WA) inserted into an intercostal muscle. Heart rate (HR) and respiration rate (RR) were obtained by filtering the recorded electrical signal. For RR measurement, the respiratory electromyogram was recorded, and RR was extracted by band pass filter and integrated within a increment of 0.3 s. The electrocardiogram (HR) was isolated from the electromyogram by frequency analysis.
Lumbar sympathetic nerve activity. The lumbar sympathetic nerve was exposed through an abdominal incision, and the nerve was dissected free of surrounding connective tissue. A thin film was placed under the nerve, and silver recording electrodes were placed on the nerve to measure LSNA. After the optimal nerve signal was confirmed using auditory monitoring, silver recording electrodes were glued to the nerve with silicon gel (Kwik-Sil; World Precision Instruments, Sarasota, FL). The raw nerve signal was filtered, amplified, rectified, and then integrated online, and the integrated nerve signal was displayed in real time. Data were recorded using signal-processing software and analyzed with LabChart (PowerLab; ADinstruments; Colorado Springs, CO).
Modeling of HR, RR, and LSNA profiles. Curve fitting was accomplished using Kaleida Graph software (Synergy Software) and was performed on HR and LSNA data using a one-component model:
The assessment of goodness-of-fit for the model was performed as detailed above for Pmv O 2 .
Measurement Protocol 3: BP Measurement (n ϭ 14)
A PE-50 catheter filled with heparinized saline was inserted in the right carotid artery to record arterial blood pressure via a pressure transducer (DX-100; Nihon Kohden). The pressure signals were continuously sampled at 1 kHz with a PowerLab (PowerLab; ADinstruments) and recorded on a computer using Chart software. HR was derived from the arterial systolic peaks, and mean arterial pressure (MAP) was calculated online. The BP was calibrated accounting for the pressure changes in the chamber. The range of this measurement system was 1.0 -1.4 ATA, and hence no measurements were collected in the pressure interval above 1.4 ATA.
Statistical Analysis
All experimental data are expressed as means Ϯ SE. All statistical analyses were performed in Prism version 6.01 (GraphPad Software, San Diego, CA). Significant differences were identified by a two-way repeated-measures ANOVA and Bonferroni post hoc test, and significant main effects of diabetes or significant interaction between diabetes and each pressure condition are shown for Pmv O 2 , HR, RR, LSNA, and BP. Differences between model parameter estimates [i.e., TD, , mean response time (MRT), etc.] were determined by twotailed unpaired t-test. Significance was accepted at P Յ 0.05.
RESULTS
Blood glucose concentration was 83 Ϯ 4 (range of 65-97) and 408 Ϯ 19 (range of 302-600) mg/dl in CONT and DIA, respectively (P Ͻ 0.01). DIA rats evidenced a significant decrease in body weight at 4 -6 wk post-STZ injection compared with CONT (CONT: 263.9 Ϯ 6.2, DIA: 217.5 Ϯ 4.5 g, P Ͻ 0.01).
Pmv O 2 Kinetics
There was no significant difference in baseline Pmv O 2 at normal atmospheric pressure between CONT and DIA rats (CONT: 22.9 Ϯ 4.2, DIA: 27.8 Ϯ 3.3 Torr, P Ͼ 0.05) (Fig. 2) . However, the profile of Pmv O 2 at the onset of HBO (from Pre to hyperoxia condition) was substantially different between CONT and DIA rats. Specifically, on exposure to the 100% O 2 , Pmv O 2 in DIA rats increased more rapidly (i. 
HR Response to HBO
Resting HR in DIA rats was decreased at 4 wk after STZ injection (P Ͻ 0.01 vs. CONT). As shown in Fig. 3B , both CONT and DIA rats decreased HR during the switch from room air to the pressurization phase. However, the observed bradycardia occurred far faster in CONT than DIA (i.e., the TD and MRT were ϳ500 and ϳ300% longer, respectively, for DIA). Upon resumption of normobaric normoxia, the bradycardia was relieved, and HR recovered to pre-HBO levels in CONT rats (Pre: 370 Ϯ 189, Post 4: 380 Ϯ 18 beats/min, P Ͼ 0.05). On the other hand, the bradycardic response of DIA rats persisted at Post 4 (Pre: 325 Ϯ 20, Post: 314 Ϯ 18 beats/min, P Ͻ 0.05).
RR Response to HBO
A rapid decrease of RR was observed concomitant with the onset of hyperoxia in both CONT (Pre/normoxia: 84.9 Ϯ 4.8 breaths/min, hyperoxia: 56.9 Ϯ 6.0 breaths/min) and DIA (Pre/normoxia: 91.7 Ϯ 2.6 breaths/min, hyperoxia: 79.2 Ϯ 2.1 breaths/min) rats. TD and were extended in DIA rats compared with CONT rats such that the mean response time increased ϳ500% (P Ͻ 0.05, Fig. 4B ). CONT RR fell to a lower value under Pre/hyperoxia conditions. However, by the 1.4 ATA condition RR was identical in CONT and DIA groups and subsequently stabilized 15-20% below the normoxic normobaric baseline and was not significantly different between groups thereafter.
LSNA Response to HBO
The proportional change in LSNA from Pre/normoxia to HBO was not significantly different between CONT and DIA rats (CONT: 62.3 Ϯ 3.0%, DIA: 53.0 Ϯ 11.4% at 3.0 ATA, Fig. 5A ). However, as evident in Fig. 5B , the dynamic profile of LSNA from Pre to the 3.0 ATA condition was substantially different between CONT and DIA rats. Specifically, was far longer in DIA rats (CONT: 34.5 Ϯ 12.5 s, DIA: 141.8 Ϯ 22.0 s, P Ͻ 0.05) such that the mean response time increased by ϳ75% (P Ͻ 0.05). During the depressurization phase, LSNA in CONT rats increased and returned to approximately baseline levels (Post 4: 90.0 Ϯ 6.0%), whereas LSNA in DIA rats evidenced a robust elevation that was not resolved by Post 4 (Post: 166.0 Ϯ 45.5%).
BP Response to HBO
MAP of the DIA rats was significantly lower at Pre/normoxic baseline (CONT: 121 Ϯ 3 mmHg, DIA: 103 Ϯ 6 s, P Ͻ 0.05). MAP rose significantly in DIA at 1.4 ATA HBO but remained substantially ϳ20 mmHg below that of CONT rats for all mea- 
DISCUSSION
The major original findings of this investigation are that HBO raises muscle Pmv O 2 in Type 1 diabetic rats to levels commensurate with those found in their healthy CONT counterparts. Moreover, the Pmv O 2 response to normobaric hyperoxia and HBO in DIA is significantly faster at the onset of hyperoxia and slower on the return to normobaric normoxia actually increasing muscle exposure to the hyperoxic environment. The differences between CONT and DIA Pmv O 2 corre- spond temporally to sluggish respiratory and sympathetic nerve responses operating in concert with the presiding DIA-induced bradycardia and hypotension. These latter effects presumably combine with any aberrant vascular control mechanisms that may alter the vasoconstrictive response to hyperoxia and HBO.
Measurement of Pmv O 2 by Phosphorescence Quenching During HBO
Tissue O 2 measurements during HBO have historically employed micro-O 2 electrodes (7) and percutaneous PO 2 techniques (13) . The advantages of the present phosphorescence quenching technique (36) are powerful. 1) As the R2 phosphor is restricted to the vascular compartment consequent to its binding to albumin and negative charge, the signal is not contaminated by what may be extremely low intracellular PO 2 values (31). 2) Other than infusing R2 in the blood and exposing the surface of the muscle, this method is noninvasive, and its calibration is absolute in living tissue (12) .
3) The measurements have high temporal fidelity and do not compromise hemodynamic stability even in small animals. One putative concern was that, in a hyperoxic environment, the phosphorescent signal intensity may be too low for effective measurement. However, at no time was the signal intensity inadequate to measure Pmv O 2 even at the most extreme HBO condition (i.e., 100% O 2 , 3.0 ATA).
Pmv O 2 Measurements
Baseline (Pre/normobaric normoxia). As presented in the Introduction, previous evidence supports that Type 1 diabetes causes extreme structural and functional alterations in the muscle microcirculation. Specifically, the reduction of capillary internal diameter observed in DIA impairs the normal capillary hemodynamics (16, 38) . However, Pmv O 2 reflects the balance between Q O 2 and V O 2 per unit volume of muscle. Thus, the substantial muscle atrophy incurred by DIA acts to increase capillary density and preserve capillary volume density (38) and Q O 2 (8, 40) , even in the presence of a greater proportion of non-or low-red blood cell-flowing capillaries. Consequently, although DIA can reduce resting muscle Pmv O 2 , this response was not evident herein (Fig. 2) .
The hyperoxia/HBO response. Certainly under resting conditions in CONT muscle no supply dependency of metabolism (V O 2 ) is expected, and so any increase in Pmv O 2 will result directly from an elevated arterial O 2 content and any changes in blood flow (i.e., Q O 2 ) to the anterior tibialis muscle (Fig. 2) . Using the ideal alveolar gas equation for an alveolar and arterial PCO 2 of 40 Torr and assuming the respiratory exchange ratio is 0.8, the pulmonary end-capillary PO 2 would be 99 Torr in normobaric normoxia (Pre condition). This value would rise to 663 Torr for normobaric hyperoxia and, in the extreme, to 2,183 Torr at 3 ATA HBO. Thus, considering that Hb is 98% saturated with O 2 in normobaric normoxia and 100% in normobaric hyperoxia, at a Hb concentration of 15 g/100 ml, this constitutes an additional 0.4 ml O 2 /100 ml to arterial content. According to Henry's law, the portion dissolved in plasma will be the presiding PO 2 ϫ 0.003 ml·Torr Ϫ1 ·100 ml
Ϫ1
. This dissolved O 2 will rise from 0.3 ml in normobaric normoxia to 2.0 ml in normobaric hyperoxia and then sequentially to 6.5 ml/100 ml at 3 ATA HBO.
In CONT anterior tibialis muscle Pmv O 2 increased systematically to 1.2 ATA, reflecting the hyperoxic arterial PO 2 loading more O 2 on Hb and also in the plasma. Beyond that, there was a more gentle and approximately linear rise with increased pressure to 2.6 ATA. This overall profile contrasted sharply with the sharp and continued Pmv O 2 increase to ϳ113 Torr at 1.4 ATA in DIA muscle. We surmise that the difference in these two profiles is likely to be the combination of differential vasomotor control within DIA muscle (i.e., slowed rate of vasoconstriction) with additional contributions from the impaired cardiorespiratory and sympathetic nervous system responses.
Vasomotor control. The vasoconstrictive response to hyperoxia (41) has been attributed to inhibition of prostaglandin production by elevated reactive O 2 species (35) and also downregulation of the adenosinergic pathway (increased plasma adenosine deaminase) as well as T cell surface CD26 activity (6) . The precise interplay between these controllers in HBO remains to be characterized in health (or DIA). Notwithstanding that, it is extremely likely that the DIA state, with its proinflammatory nature, impacts these aspects of vasomotor control and, in particular, compromises the ability to respond rapidly to altered muscle metabolic demands. In contrast, one aspect of vasomotor control that appears to be enhanced in Type 1 DIA is the elevated arteriolar myogenic tone that is conferred, in part, by smooth muscle voltage-dependent Ca 2ϩ channels and protein kinase C (43) . Although no formal kinetics analysis was undertaken in that investigation, the rat gracilis arterioles ϳ100 m examined demonstrated a greater response to increased luminal pressure that was at least as rapid in DIA as CONT. In these same vessels there was impaired endothelial function in the presence of heightened norepinephrine-induced vasoconstriction (43) . Thus, at present, there is no clear mechanistic answer to why the time course of HBOinduced vasoconstriction, as inferred from the Pmv herein, may be impaired in DIA. On the other hand, the vascular adaptation dynamics in response to increased muscle energetic demands in DIA are slowed (2) , and microcirculatory function is compromised (16, 27 (Fig. 4, reviewed in Ref. 46) . However, the impact of this will be relatively modest and will depend on the degree to which the decline in RR influences alveolar ventilation allowing alveolar PCO 2 to rise. Thus, if tidal volume remains unchanged and the ϳ40% decrease of RR seen in CONT lowers alveolar ventilation by a similar amount, this would reduce the normobaric hyperoxic end-pulmonary capillary PO 2 from ϳ660 to ϳ590 mmHg. In DIA this response had a delayed onset (TD, CONT 3 Ϯ 1 vs. DIA 18 Ϯ 3 s) and was overall slowed (MRT, CONT 6 Ϯ 1 vs. DIA 29 Ϯ 4 s) and less pronounced (ϳ20%). This effect results from a desensitization of the carotid bodies by hyperglycemia (9, 14) and would act to reduce the fall in PO 2 by only ϳ20 mmHg. Thus, the RR response to HBO could not account for a sizeable portion of the DIA Ϫ CONT difference in Pmv O 2 . Despite the apparent similarity in the averaged time courses of HR (Fig.  3A) and LSNA (Fig. 5A) , inspection of the precise time course in Figs. 3B (MRT, CONT 16 Ϯ 1 vs. DIA 45 Ϯ 5 s) and 5B (MRT, CONT 140 Ϯ 16 vs. DIA 247 Ϯ 34 s), respectively, reveals a profound sluggishness in their responses to the normobaric hyperoxia and HBO. These effects will impact muscle Q O 2 in opposite ways. Thus, following initiation of the hyperoxic conditions, and, unless stroke volume falls, which is unlikely, HR and cardiac output will have decreased less for DIA and thus may be contributing to the elevation of tibialis anterior Q O 2 in DIA vs. CONT. It is pertinent that this response occurs against a background of hypotension in DIA (Fig. 6 ), which will act to reduce inflowing muscle arterial pressure and flow. HBO does relieve this hypotension slightly with the increased MAP during HBO (Fig. 6 ) that results presumably from the elevated systemic vascular resistance mediated partially through arterial baroreceptor activation (10) . In contrast to the above, the slowed withdrawal of LSNA (Fig. 5) , which constitutes the primary sympathetic innervation of the limb vasculature (25), will certainly not act to elevate Q O 2 , and therefore Pmv O 2 in DIA vs. CONT, and cannot therefore explain the divergent Pmv O 2 response seen in DIA (Fig. 2) . It was interesting that, upon resumption of normobaric normoxia in DIA, the LSNA was substantially increased, and this corresponded temporally with continued elevation of Pmv O 2 . It is pertinent that dysfunctional baroreflex control has been reported in animal models of diabetes mellitus (9, 39). Thus, it is possible that this LSNA hyperactivity in DIA following termination of HBO exposure may be associated with hyposensitivity of the baroceptors.
In summary, either the small impact of the respiratory response or the directionally opposed nature of the LSNA differences disqualify these mechanisms from contributing substantially or at all to the elevated Pmv O 2 seen in DIA vs. CONT during the initial hyperoxic/HBO exposure. In contrast, the slowing of the HBO-induced reduction in HR could potentially account for some of the observed transient elevation of Pmv O 2 in DIA vs. CONT. However, the modest size of this effect suggests a primary intramuscular vasomotor etiology.
Perspectives and Significance
Our expectation that the impaired vasomotor control in DIA muscle would lead to a faster increase of Pmv O 2 during HBO was substantiated. However, beyond the transient, and under conditions from normobaric hyperoxia up to 3 ATA, HBO Pmv O 2 levels were certainly no lower (or higher) for DIA than CONT. Interestingly, during recovery in normobaric normoxia, Pmv O 2 remained elevated longer in DIA than CONT. These muscle oxygenation differences likely relate primarily to altered vasomotor control within the muscle, since they could not be explained adequately by the respiratory, cardiovascular, or sympathetic responses. As with many therapeutic approaches, HBO therapy in DIA is a double-edged sword, with the occurrence of both harmful oxidative stress (22, 23) and the initiation of palliative cell signaling cascades that help restore tissue integrity (21, 42) . A greater understanding of the relationship between HBO-induced Pmv O 2 elevations (i.e., signal) and both pernicious and helpful oxidative stress/signaling pathway activation (i.e., response) will help define optimal HBO treatment regimens for reducing morbidity in DIA patients.
In conclusion, despite severe structural and functional pathology, HBO raises Pmv O 2 at least as effectively, and possibly more so, in DIA muscle compared with that of CONT animals. Therefore, HBO therapy certainly has the potential to initiate cell signaling cascades that promote angiogenesis and wound healing within skeletal muscle.
